Oncolytics Biotech® Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically 'cold' tumors 'hot' through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact.
Company News|Latest News, Press and Market Commentary
Bloomberg|News
CNBC|News
Market Chart
Oncolytics Biotech® Inc.
Oncolytics Biotech® Inc. is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic designed to activate anti-cancer immune responses. Pelareorep works by converting immunologically 'cold' tumors into 'hot' tumors through the stimulation of innate and adaptive immune pathways. The therapy has demonstrated encouraging results across multiple clinical programs, including pancreatic and metastatic breast cancer, as well as early-stage studies in anal and colorectal cancers. Oncolytics is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors in metastatic gastrointestinal cancers, where it has received FDA Fast Track designation for colorectal and pancreatic indications. The company is actively pursuing strategic partnerships to accelerate development and maximize commercial potential.
Market Summary
Biotechnology sector driven by innovation in therapeutics and life sciences.
Strong institutional interest due to high-growth and breakthrough potential.
Pipeline-driven valuations with catalysts tied to clinical milestones.
Advancements in immunotherapy and precision medicine shaping sector growth.
Industry Insights
Biotechnology companies play a critical role in advancing global healthcare innovation.
Firms focus on developing new therapeutics, diagnostics, and biomedical technologies.
The sector is driven by breakthroughs in immunotherapy and precision medicine.
Clinical trial results and regulatory approvals act as major valuation catalysts.
Institutional capital is attracted by long-term growth and innovation potential.
Biotech sits at the forefront of next-generation medical and scientific advancement.
Industry Leaders
Eli Lilly
LLYGlobal pharmaceutical leader in obesity, diabetes, and oncology.
Novo Nordisk
NVOLeader in diabetes care and GLP-1 therapies.
Johnson & Johnson
JNJDiversified healthcare and pharmaceutical giant.
Merck & Co.
MRKOncology and vaccine powerhouse (Keytruda).
AbbVie
ABBVImmunology and oncology-focused biopharma company.
Amgen
AMGNBiotech leader in biologics and biosimilars.
Gilead Sciences
GILDAntiviral and oncology-focused biotech.
Regeneron Pharmaceuticals
REGNInnovative biotech in immunology and eye care.
Vertex Pharmaceuticals
VRTXLeader in cystic fibrosis and gene-based therapies.
Moderna
MRNAmRNA platform biotechnology company.
Sector Stocks
Replimune Group
REPLOncolytic immunotherapy development.
ORIC Pharmaceuticals
ORICTargeted cancer therapies.
Anixa Biosciences
ANIXCancer immunotherapy and vaccines.
ImmunityBio
IBRXCell-based immunotherapy platform.
Iovance Biotherapeutics
IOVATumor-infiltrating lymphocyte therapies.
Precigen
PGENGene and cell therapy platform.
Exelixis
EXELCancer-focused biotech therapeutics.
Incyte
INCYOncology and inflammation treatments.
BridgeBio Pharma
BBIOGenetic disease therapeutics.
Krystal Biotech
KRYSGene therapy innovation.
Kymera Therapeutics
KYMRTargeted protein degradation platform.
Moderna
MRNAmRNA-based therapeutics and vaccines.
Regeneron Pharmaceuticals
REGNBiologic drug development leader.
Vertex Pharmaceuticals
VRTXGenetic disease therapies.
BioMarin Pharmaceutical
BMRNRare disease treatments.
Alnylam Pharmaceuticals
ALNYRNA interference therapeutics.
Trading Platforms
TradingView
Advanced charting and technical analysis platform.
Interactive Brokers
Global trading across equities, options, and futures.
eToro
Social trading and multi-asset investing platform.
TD Ameritrade
Retail trading with thinkorswim tools.
Charles Schwab
Full-service brokerage and investment platform.
Robinhood
Commission-free trading app for retail investors.
Trade Republic
European mobile-first investing platform offering stocks, ETFs, and savings plans.
Stash
Beginner-friendly investing app with automated portfolios and education tools.
TradeStation
Advanced trading platform with powerful analytics and execution tools.
XS.com
Global multi-asset broker offering forex, commodities, and indices trading.
CityFalcon
AI-driven financial news aggregation and market intelligence platform.
Webull
Mobile-first trading with advanced analytics.
Plus500
CFD trading platform for global markets.